Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01830127 · ClinicalTrials.gov registry record · Phase 2
BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT01830127 is a Phase 2 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 35 participants.
The verdict
NCT01830127, a Phase 2 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
To assess the pharmacokenetic characteristics of 600 mg BID BI 207127 / 120 mg QD faldaprevir /ribavirin in a small number of GT1b HCV infected patients with mild hepatic impairment (CPA) (Arm 1) versus 400 mg BID BI 207127 / 120 mg QD faldaprevir /ribavirin in a small number of GT1b HCV infected patients with moderate hepatic impairment (CPB) (Arm 2).
Interventions
- DRUG Ribavirin
- DRUG Faldaprevir
- DRUG BI 207127 high dose
- DRUG BI 207127 low dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2013-04 |
| Est. Completion | 2014-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01830127
The ClinicalTrials.gov registry entry for NCT01830127 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Ribavirin is the first listed.
NCT01830127 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01830127 about?
NCT01830127 is a clinical study titled "BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3". To assess the pharmacokenetic characteristics of 600 mg BID BI 207127 / 120 mg QD faldaprevir /ribavirin in a small number of GT1b HCV infected patients with mild hepatic impairment (CPA) (Arm 1) versus 400 mg BID BI 207127 / 120 mg QD faldaprevir /ribavirin in a small number of GT1b HCV infected pa...
What is the current status of trial NCT01830127?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2013-04. Estimated completion is 2014-10.
What interventions are being tested in trial NCT01830127?
The interventions under investigation include: Ribavirin (DRUG), Faldaprevir (DRUG), BI 207127 high dose (DRUG), BI 207127 low dose (DRUG).
Who is sponsoring clinical trial NCT01830127?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.